Annual changes of pathogen and antimicrobial susceptibility of causative bacteria isolated from patient with cholecystitis, cholangitis, severe acute pancreatitis

Annual changes of pathogen and antimicrobial susceptibility of causative bacteria isolated from patient with cholecystitis, cholangitis, severe acute pancreatitis - Annual changes of pathogen and antimicrobial susceptibility of causative bacteria isolated from patient with cholecystitis, cholangitis, severe acute pancreatitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005104

Enrollment

Registered

2011-02-18

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholecystitis, Cholangitis, severe Acute pancreatitis

Interventions

Choler, Blood culture Administration of antibiotic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatient aged 20 or over regardless of gender

Exclusion criteria

Exclusion criteria: (1) Cases with severe cardiac, hepatic, renal function disorder (2) Cases with a history of allergy to B-lactam antibiotics (carbapenems,cephems, penicillins, etc) (3) Cases pregnant, lactating or suspected of being pregnant (4) Cases which therapeutic response of B-lactam antibiotics can not be expected (caused by virus, mycoplasma, chlamydia and fungus) (5) Cases treated with sodium valproate or with central nervous system damage such as epilepsia (6) Cases which need combined usage of diuretic such as furosemide (7) Cases with improvement by previous treatment of antimicrobial agent (8) Cases with similar infectious episode of ineffective treatment with carbapenem antibiotics (9) Other cases which doctor in charge regard inadequate to include in the study

Design outcomes

Primary

Measure	Time frame
Causative bacteria and antimicrobial susceptibility before and after antimicrobial administration Clinical response and safety of day 3 and day 7 after Biapenem is administered	—

Countries

Japan

Contacts

Public ContactShoji Watanabe

Nagaoka Chuo Hospital Koseiren,Niigata-Ken internal medicine

shownabe@nagachu.jp0258-35-3700

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026